Altimmune, Inc. — Director's Dealing 2025

Feb 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2025-02-06

Reporting Person: Sohn Catherine A. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-06	Stock Options (option to buy)	$6.91	A	18600	Acquired	2035-02-06	Common Stock, par value $0.0001 (18600)	Direct

Footnotes

F1: The shares underlying the option shall vest as follows: (i) 50% on July 15, 2025, (ii) 25% on September 30, 2025 and 25% on December 31, 2025, subject to the reporting person's continued service through the applicable vesting date.